Guardant Health Expands Cancer Test Access with PathGroup Deal

Guardant Health has expanded access to its cancer test, Shield, through a deal with PathGroup. The precision oncology company provides critical insights into cancer through blood and tissue tests, real-world data, and AI analytics. Its tests improve outcomes across all stages of care, including screening, monitoring, and treatment selection for patients with advanced cancer. Guardant360 is a comprehensive liquid biopsy test used as a companion diagnostic for NSCLC and breast cancer.